Derby, United Kingdom — The administration of THCV (tetrahydrocannabivarin), a non-psychoactive component of cannabis, is positively associated with glycemic control in type 2 diabetics, according to the randomized, placebo-controlled data published in the journal Diabetes Care.
Investigators from the University of Nottingham, School of Medicine assessed the twice daily administration of various cannabinoids (CBD or THCV or CBD and THCV in combination) versus placebo over a period of 13 weeks in 62 non-insulin dependent subjects with type 2 diabetes.
Authors reported that the administration of THCV alone “significantly decreased fasting plasma glucose” levels and improved pancreatic cell function. By contrast, other treatment therapies failed to show detectable metabolic effects.
Investigators concluded, “THCV could represent a new therapeutic agent in glycemic control in subjects with type 2 diabetes.”
Population-based observational studies have previously reported that cannabis consumers typically possess lower BMI and other favorable indices related to diabetic control compared to those without a history of marijuana use.
For more information, please contact Paul Armentano, NORML Deputy Director, at: firstname.lastname@example.org. Full text of the study, “Efficacy and safety of cannabidiol and tetrahydrocannabivarin on glycemic and lipid parameters in patients with type 2 diabetes: A randomized, double-blind, placebo-controlled parallel group pilot study,” appears in Diabetes Care.